- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer CEO Albert Bourla tests COVID positive
![Pfizer CEO Albert Bourla tests COVID positive Pfizer CEO Albert Bourla tests COVID positive](https://medicaldialogues.in/h-upload/2022/08/16/750x450_183404-albert-bourla.webp)
New York: Pfizer Inc Chief Executive Officer Albert Bourla has said that he had tested positive for COVID-19 and was experiencing very mild symptoms.
Bourla said he had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid, and was isolating and following all public health precautions.
Read also: S Sridhar resigns as MD of Pfizer
Paxlovid is an antiviral medication that is used to treat high-risk patients, such as older people.
Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech.
Read also: Pfizer to purchase Global Blood Therapeutics for USD 5.4 Billion
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story